KalVista applies deep expertise in the kallikrein-kinin system to develop breakthrough oral medicines that address the full spectrum of HAE management. The company is well-positioned as the only player with an FDA-approved oral on-demand HAE treatment, creating competitive moat potential in a growing rare disease market with limited therapeutic options.
Cyborg Score Rationale
KalVista demonstrates strong fundamentals with first-mover advantage in a large, unmet-need market and early revenue momentum from EKTERLY launch. Pipeline expansion into HAE prophylaxis and potential for market expansion support the positive outlook, though execution risk and commercial competition remain considerations.
Top Insights
EKTERLY launched in 2025 and is generating meaningful revenue with preliminary full-year 2025 results showing strong traction
Only FDA-approved oral on-demand treatment for HAE creates significant competitive advantage and market leadership position
Pipeline includes oral Factor XIIa inhibitor for HAE prophylaxis, positioning the company across full disease management spectrum
Company has over 250 employees globally with decade-long focus on HAE, demonstrating commitment and domain expertise
Named Competitors
HAE Therapies — Developing therapies for rare diseases including HAE
HAE Treatments — Develops therapies for hereditary angioedema
Recent Developments
(February 2026) Presented EKTERLY data at 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting